Importance of bone assessment and prevention of osteoporotic fracture in patients with prostate cancer in the gonadotropic hormone analogues use;Importância da avaliação óssea e da prevenção da fratura osteoporótica em pacientes com câncer de proìstata em uso de anaìlogos do hormônio gonadotrófico

Revista do Colegio Brasileiro de Cirurgioes

Volumn 42, Issue 1, 2015, Pages 62-66

  Cançado, Bruno Lopes ^a   Miranda, Luiz Carlos ^a   Madeira, Miguel ^a   Farias, Maria Lucia Fleiuss ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Gonadotropin releasing hormone analogues derivatives; Hormones; Osteoporosis; Prostatic neoplasms; Testosterone antagonists inhibitors

Indexed keywords

ANTIANDROGEN; GONADORELIN;

ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; HUMAN; MALE; OSTEOPOROTIC FRACTURES; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROTIC FRACTURES; PROSTATIC NEOPLASMS;

EID: 84929353773     PISSN: 01006991     EISSN: 18094546     Source Type: Journal    
DOI: 10.1590/0100-69912015001012     Document Type: Review

References (45)

1. Faria EF, Carvalhal GF, Vieira RA, Silva TB, Mauad EC, Tobias-Machado M, et al. Comparison of clinical and pathologic findings of prostate cancers detected through screening versus conventional referral in Brazil.ClinGenitourin Cancer. 2011;9(2):104-8.
2. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgensensitive non metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J ClinOncol. 2007;25(12):1596-605.
3. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29(4):411-64.
4. DavidgePitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc. 2011;86(4):338-43.
5. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J ClinEndocrinolMetab. 2012;97(6):1802-22.
6. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgendeprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100(5):892-9.
7. Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist. 2006;11(10):1121-31.
8. Body JJ, Bergmann P, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer — a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18(11):1439-50.
9. Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat ClinPract Urol. 2008;5(1):24-34.
10. Body JJ. Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol. 2010;21 Suppl 7:vii180-5.
11. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013;189(1 Suppl):S34-42; discussion S43-4.
12. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79(3):542-50.
13. Peters JP, Fairney A, Kyd P, Patel A, Rogers S, Webster JJ, et al. Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis. 2001;4(3):161-6.
14. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;25(3):389-425.
15. Falahati-Nini A, Riggs BL, Atkinson EJ, O’Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106(12):1553-60.
16. Ferlin A, Selice R, Carraro U, Foresta C. Testicular function and bone metabolism—beyond testosterone. Nat Rev Endocrinol. 2013;9(9):548-54.
17. Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men. J Clin Endocrinol Metab. 2001;86(6):2869-74.
18. Tanaka T, Latorre MR, Jaime PC, Florindo AA, Pippa MG, Zerbini CA. Risk factors for proximal femur osteoporosis in men aged 50 years or older. Osteoporos Int. 2001;12(11):942-9.
19. Lopes RF, Ferreira SA, Coeli CM, Farias ML. Low body mass index and declining sex steroids explain most age-related bone loss in Brazilian men. Osteoporos Int. 2009;20(7):1175-82.
20. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91(12):2238-45.
21. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(3 Suppl):789-95.
22. National Osteoporosis Foundation. 2013 Clinician’s guide to prevention and treatment of osteoporosis [Internet]. Washington, DC: NationalOsteoporosis Foundation. [Acessado: 14 dez 2013]. Disponível em: http://nof.org/files/nof/public/content/resource/913/files/580.pdf
23. Pinheiro MM, Ciconelli RM, Martini LA, Ferraz MB. Clinical Risk factors for osteoporosis fractures in Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Osteoporos Int. 2009;20(3):399-408.
24. Pinheiro Mde M, Ciconelli RM, Martini LA, Ferraz MB. Risk factors for recurrent falls among Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Cad SaudePublica. 2010;26(1):89-96.
25. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86(4):449-52.
26. Diamond TH, Bucci J, Kersley JH, Aslan P, Lynch WB, Bryant C. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004;172(2):529-32.
27. Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology. 2004;64(6):1182-6.
28. Brasil. Ministério da Saúde. Instituto Nacional de Câncer José de Alencar Gomes da Silva. Estimativa 2014: incidência do câncer no Brasil [Internet]. Rio de Janeiro: INCA. 2013. [Acessado: 07 mai 2014]. Disponível em: http://www.inca.gov.br/estimativa/2014/sintese-de-resultados-comentarios.asp
29. United States of America. Center for Diseases Control and Prevention. Prostate Cancer: Prostate Cancer Statistics [Internet]. Chamblee: CDC 2013. [Acessado: 14 dez 2013]. Disponível em: http://www.cdc.gov/cancer/prostate/statistics/index.htm
30. United States of America. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-v.2.2014. Prostate Cancer [Internet]. Fort Washington: NCCN.org. [Acessado: 02 jan 2014]. Disponível em: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
31. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166(5):1724-8.
32. Charles B., Huggins, MD, 1901-1997. Acessado em 14 de dezembro de 2013. Disponível em: http://www.uchospitals.edu/news/1997/19970113-huggins.html
33. Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, et al.Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36-44.
34. Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, et al. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer. Urology. 2004;64(1):128-31.
35. Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. UrolClin North Am. 2012;39(4):533-46.
36. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur Urol. 2013;63(5):927-35.
37. Cançado BL, Miranda LC, Fleiuss ML, Madeira M. Bone mineral density in prostate cancer patients with drug induced hypogonadism. J EndocrinolDiabetes Obes. 2014;2(1):1017.
38. Weston R, Hussain A, George E, Parr NJ. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer. BJU Int. 2005;95(6):776-9.
39. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111(4):543-8.
40. Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005;103(2):237-41. Erratum in: Cancer. 2006;106(11):2530.
41. Unger MD, Cuppari L, Titan SM, Magalhães MC, Sassaki AL, dos Reis LM, et al. Vitamin D status in a sunny country: where has the sun gone? ClinNutr. 2010;29(6):784-8.
42. Pereira RM, Carvalho JF, Paula AP, Zerbini C, Domiciano DS, Gonçalves H, et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.Rev Bras Reumatol. 2012;52(4):569-93.
43. Lee CE, Leslie WD, Lau YK. A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy. BMC Cancer. 2012;12:103.
44. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. NEngl J Med. 2009;361(8):745-55.
45. Araújo DV, Oliveira JHA, Bracco OL. Custo da fratura osteoporótica de fêmur no sistema suplementar de saúde brasileiro. Arq Bras Endocrinol Metab. 2005;49(6):897-901.